Bariatric Surgery
If you have been struggling with your weight, and diet and exercise have not yielded the desired results, there are a variety of options available to you, including bariatric surgery. Bariatric surgery may encompass a variety of procedures, which are collectively designed to help you lose weight. One common form of bariatric surgery is known as gastric bypass, which involves changing how your digestive system operates. Through these changes, your body may be better equipped to lose weight and maintain a healthier lifestyle. Bariatric surgery may also be recommended if you are experiencing health problems due to your weight. By speaking to your healthcare provider about the benefits and risks of these procedures, you can make a more informed decision about the best course of action for your personal health and wellness needs.
News

Planning to Stop Taking a GLP-1? Here’s How to Maintain Weight Loss
Research shows that having an “exit strategy” after stopping at GLP-1 can help maintain your weight loss. coldsnowstorm · E+/Getty
A Cleveland Clinic study found that bariatric surgery and switching GLP-1 medications were associated with greater weight loss than discontinuing treatment entirely.
After two years, participants who underwent bariatric surgery lost an average of 28.2% of their body weight, compared with 16% among those who switched between semaglutide and tirzepatide and 4% among those who stopped GLP-1 treatment.
Stopping a GLP-1 medication can lead to increased hunger and weight regain. Experts recommend working with a healthcare professional to develop a long-term weight management plan before discontinuing treatment.
Switching GLP-1 medications or undergoing bariatric surgery may help people maintain greater weight loss than stopping treatment entirely, according to a new study presented at ObesityWeek and published in eClinicalMedicine on November 14.
The Cleveland Clinic study compared five strategies for managing weight after treatment with GLP-1 medications, analyzing data from 20,486 adults with obesity or type 2 diabetes.
People who stop taking GLP-1 medications often regain weight. Researchers examined whether continuing treatment, switching medications, or undergoing bariatric surgery could help limit weight regain or support further weight loss.
The findings showed that people who underwent bariatric surgery or switched between semaglutide (Ozempic) and tirzepatide (Zepbound) experienced the greatest overall weight loss.
Bariatric surgery and switching GLP-1s led to greater weight loss
The study participants had an average age of 56.7 years, an average weight of 109 kg (240.3 lbs), and an average body mass index (BMI) of 38. All had been taking either semaglutide or tirzepatide for at least 90 days.
The researchers categorized the participants into five groups:
continuation
switching between semaglutide and tirzepatide
switching to another weight-loss medication
undergoing bariatric surgery
discontinuation
After 2 years, those who underwent bariatric surgery saw an average loss of 28.2% of their body weight or about 31.5 kg (69.4 lbs).
“We increasingly view medications and surgery as complementary tools rather than competing ones,” said Mir Ali, MD, medical director of MemorialCare Surgical Weight Loss Center at Orange Coast Medical Center in Fountain Valley, CA, who wasn’t involved in the study.
“For patients with severe obesity (typically a BMI of 35 or higher, or 30+ with metabolic conditions like type 2 diabetes), bariatric surgery remains the most durable, cost-effective intervention available,” he added. “Using a GLP-1 beforehand can safely reduce liver volume and lower surgical risk, while surgery provides the permanent anatomical and hormonal reset needed to maintain that weight loss long-term without relying indefinitely on weekly injections.”
During the same period, those who switched between semaglutide and tirzepatide lost 16% of their body weight, or about 18 kg (39.6 lbs).
Participants who switched from semaglutide to tirzepatide lost 3 kg (6.6 lbs) more than those who continued taking semaglutide. However, participants already taking tirzepatide lost 4.5 kg (9.9 lbs) more by continuing treatment rather than switching to semaglutide.
The other groups experienced lower amounts of weight loss:
Continuation of initial GLP-1 medication: average of 10.9% of their body weight or 12.3 kg (27.1 lbs)
Switching to another weight loss medication: average of 8.2% of their body weight or 9.2 kg (20.2 lbs)
Total discontinuation of a GLP-1 medication: average of 4% of their body weight or 4.5 kg (9.9 lbs)
After one year, participants with type 2 diabetes experienced HbA1c reductions of 1.76% following bariatric surgery, 1.43% after switching GLP-1 medications, and 1.32% after continuing their original medication, compared with 0.48% among those who discontinued treatment entirely.
After one year, participants with hypertension (high blood pressure) also experienced greater reductions in blood pressure following surgery or switching GLP-1 medications than those who discontinued treatment entirely.
“[This study] reinforces the need for a long term, multi-modal continuum of care rather than treating GLP-1s as a temporary fix,” said Ali.
Other options for continued weight loss after GLP-1s
Ali also recommended the following strategies to help maintain weight loss after stopping a GLP-1 medication:
Prioritize protein and resistance training: People who stop taking GLP-1 medications may regain body fat after losing muscle mass during treatment. Eating enough protein and regularly doing strength-training exercises can help preserve muscle mass and support metabolism.
Seek nutritional and behavioral support: Working with a registered dietitian can help people develop sustainable eating habits as the medication’s appetite-suppressing effects wear off. This may include focusing on fiber-rich foods, balanced meals, and consistent meal timing.
What to consider when thinking about stopping a GLP-1
The findings highlight the importance of having a long-term weight management plan in place before stopping a GLP-1 medication.
Before stopping a GLP-1 medication, talk with a healthcare professional. They can help you explore your options and determine which strategies may be most appropriate for your health needs.
Ali told Healthline that identifying the reason for stopping treatment is an important first step. He noted that people often discontinue GLP-1 medications because of gastrointestinal side effects, supply issues, or loss of insurance coverage rather than because they no longer need treatment.
He said that if side effects are the issue, adjusting the dose or switching to a different agent often solves the problem.
Ali also emphasized that stopping a GLP-1 medication shouldn’t be viewed as a test of willpower. Increased hunger after discontinuing treatment is a biological response, not a personal failure.
“Have a concrete ‘off-ramp’ plan in place with your doctor before taking your last dose, so you have medical, nutritional, or surgical support ready to protect the health gains you worked hard to achieve,” advised Ali.

$3,900 GLP-1 Vacation; ‘Dr. Blanche’s Dispensary’ Scrutinized; Outbreak Hits Cruise
(MedPage Today) — Note that some links may require registration or subscription.
A woman opened up about her time at a week-long, $3,900 “GLP-1 Support Experience” hosted by an island resort. (Today)
The FDA announced the launch of a program…

Inside Look at Vacations Geared Toward People on GLP-1s
Friday, November 20 – Along with focusing on diet and exercise, health and wellness resorts across the country are now catering to the millions of people using GLP-1 weight loss drugs like Ozempic, Zepbound, Wegovy and Mounjaro. The programs include cooking lessons, guided strength-training sessions, and health counseling about those weight loss medicines. NBC’s Vicky Nguyen reports for TODAY.

I Paid $3,900 To Go on a ‘GLP-1 Vacation.’ Here’s What It Was Really Like
Friday, November 20 – Woman attends a GLP-1 vacation at a resort on Hilton Head Island, South Carolina. Hotels are offering experiences for guests taking the weight-loss drugs.

Why don’t weight-loss drugs like Ozempic and Wegovy work for everyone?
Friday, November 20 – Why do Ozempic and Wegovy produce dramatic weight loss for some people but disappointing results for others? Scientists are investigating whether the body’s hidden energy-saving response could help explain the difference and unlock more effective, personalized weight-loss treatments.

GLP-1 Reduced Binge Eating
Friday, November 20 – (MedPage Today) —
The FDA approved dexmedetomidine sublingual film (Igalmi) for at…

GLP-1 Eye Warning Leaves Patients, Doctors With a Difficult Choice
Friday, November 20 – (MedPage Today) — When someone loses vision in one eye while taking a GLP-1 drug, the first priority is an urgent eye examination. If the diagnosis is non-arteritic anterior ischemic optic neuropathy (NAION), the question that follows is: should…

1 in 10 U.S. adults reported GLP-1 medication use July to August 2025
Thursday, November 19 – From July to August 2025, about one in 10 U.S. adults reported taking a glucagon-like peptide-1 receptor agonist (GLP-1 RA) medication during the past year, according to research published in Morbidity and Mortality Weekly Report.

New guidance addresses GLP-1 medication use and eating disorders
Thursday, November 19 – GLP-1 medications are widely used to treat type 2 diabetes and help some people manage their weight. These medications can reduce appetite and help people feel full sooner. Early research also suggests they may help reduce binge-eating episodes for some people.
Reviews
- Adams TD, Gress RE, Smith SC, Halverson RC, Simper SC, Rosamond WD, Lamonte MJ, Stroup AM, Hunt SC. Long-term mortality after gastric bypass surgery. N Engl J Med. 2007 Aug 23;357(8):753-61. doi: 10.1056/NEJMoa066603. PMID: 17715409.
- Gloy VL, Briel M, Bhatt DL, Kashyap SR, Schauer PR, Mingrone G, Bucher HC, Nordmann AJ. Bariatric surgery versus non-surgical treatment for obesity: a systematic review and meta-analysis of randomised controlled trials. BMJ. 2013 Oct 22;347:f5934. doi: 10.1136/bmj.f5934. PMID: 24149519; PMCID: PMC3806364.
- Courcoulas AP, Christian NJ, Belle SH, Berk PD, Flum DR, Garcia L, Horlick M, Kalarchian MA, King WC, Mitchell JE, Patterson EJ, Pender JR, Pomp A, Pories WJ, Thirlby RC, Yanovski SZ, Wolfe BM; Longitudinal Assessment of Bariatric Surgery (LABS) Consortium. Weight change and health outcomes at 3 years after bariatric surgery among individuals with severe obesity. JAMA. 2013 Dec 11;310(22):2416-25. doi: 10.1001/jama.2013.280928. PMID: 24189773; PMCID: PMC3955952.
- Brito JP, Montori VM, Davis AM. Metabolic Surgery in the Treatment Algorithm for Type 2 Diabetes: A Joint Statement by International Diabetes Organizations. JAMA. 2017 Feb 14;317(6):635-636. doi: 10.1001/jama.2016.20563. PMID: 28196240; PMCID: PMC5557277.
- Arterburn DE, Telem DA, Kushner RF, Courcoulas AP. Benefits and Risks of Bariatric Surgery in Adults: A Review. JAMA. 2020 Sep 1;324(9):879-887. doi: 10.1001/jama.2020.12567. PMID: 32870301.
References:
- Wikipedia Bariatric surgery. Accessed September 2023
- Agency for Healthcare Research and Quality. Accessed September 2023
- American Society for Metabolic and Bariatric Surgery. “Bariatric Surgery Procedures.” Accessed September 2023